Figure 1.

Effect of HAART treatment on CD8⁺ cell noncytotoxic anti-HIV activity in primary infection. The percentage of suppression of HIV-1_SF33 replication at a CD8⁺:CD4⁺ cell ratio of 0.5:1 is presented for 21 individuals experiencing the primary stages of HIV infection and receiving highly active antiretroviral therapy for a period of 24 weeks. Week 0 represents the level of CD8⁺ cell suppression before the initiation of HAART, compared with weeks 4, 12, or 24 of treatment. Statistical significance was determined by comparing the actual suppression values of all participants at week 0 with these same measurements at week 24 (P = 0.01). Red line, maintained or enhanced antiviral response; blue line, decreased antiviral response.